placebo + AK111

This is a combination of a placebo and AK111 (gumokimab), a humanized IgG1 monoclonal antibody that specifically targets interleukin-17A (IL-17A). By binding to IL-17A with high affinity, it prevents the cytokine from interacting with its receptor (IL-17RA) on immune cells such as T cells and antigen-presenting cells. This blockade inhibits downstream inflammatory signaling implicated in autoimmune diseases like moderate-to-severe plaque psoriasis and ankylosing spondylitis. The combination is used in clinical trials as part of randomized controlled studies to compare the efficacy and safety of active drug versus placebo[1][2][3][4][6].

Brand names

gumokimab

Other names

gumokimabAK 111AK111AK-111placebo + AK111